Filing Flows › ResMed (RMD) › Q3 FY26
ResMed (RMD) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed May 1, 2026
ResMed (RMD) reported revenue of $1.4B for the third quarter fiscal 2026 (Q3 FY26), +11% from a year earlier and +0.6% from the quarter before. Operating margin was 34.9%, net earnings $399M (27.9% of revenue).
ResMed, Q3 FY26: revenue $1.4B (+11% year over year), operating margin 34.9%, net earnings $399M, operating cash flow $554M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4B | +0.6% | +11% |
| Gross profit | $891M | +1% | +16% |
| Operating profit | $500M | +2% | +17% |
| Net earnings | $399M | +2% | +9% |
| Operating cash flow | $554M | +63% | -4% |
| Free cash flow | $520M | +67% | -7% |
What changed
Revenue was $1.4B in Q3 FY26, up 11% year over year and up 1% from the previous quarter. Sleep and Breathing Health was the largest line at 88% of revenue. Sleep and Breathing Health added $0.13B year over year (up 11%), 93% of the total change.
Gross margin was 62.2%, up 2.9 points from Q3 FY25. Operating profit was $0.50B, a 34.9% margin (up 1.9 points year over year). Of the extra revenue versus Q3 FY25, 53% reached operating profit, above the 33% margin then. Operating expenses grew 15% against revenue growth of 11%. The fastest-growing cost line was SG&A (+16%). Net earnings were $0.40B, up 9% year over year. The effective tax rate was 20.6%.
Operating cash flow was $0.55B (down 4% year over year), 139% of net earnings. Non-cash charges added back $0.06B of depreciation and amortization and $0.03B of share-based compensation. Working capital and other items added $0.07B. Capital expenditures of $0.03B left free cash flow of $0.52B.
Questions
What was ResMed's revenue in the third quarter fiscal 2026?
ResMed (RMD) reported revenue of $1.4B for the third quarter fiscal 2026 (Q3 FY26), +11% from a year earlier and +0.6% from the quarter before.
Was ResMed profitable in the third quarter fiscal 2026?
Operating profit was $500M (34.9% of revenue) and net earnings $399M.
Source: ResMed 10-Q on SEC EDGAR.